Compare GSK plc (GSK) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SpaceX — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 17.2× GSK plc's market cap, and GSK plc pays a 3.57% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| GSK | SPCX | |
|---|---|---|
Market Cap | $102.60B | $1.76T |
Sector | Health | Technology |
52-Week High | $61.18 | $202.09 |
52-Week Low | $38.22 | $108.27 |
Enterprise Value | $123.04B | $1.70T |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SPCX stock trades at $146.22, up 5.39% today, buoyed by strong technical momentum and positive news flow. The stock shows bullish moving average signals and trades above key support levels. Recent Q2 earnings beat expectations, though the company remains unprofitable with a net income margin of -35.66%. High-profile institutional investments, including Norway's sovereign wealth fund, underscore growing confidence in SpaceX's AI and Starlink growth trajectory.
Outlook is optimistic given analyst consensus and AI-driven revenue potential, but risks include persistent losses, high valuation multiples, and insider share unlocks. The consensus price target of $228.52 implies significant upside if execution aligns with ambitious growth plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
